Denosumab versus zoledronic acid: analgesic and survival impact of an extended treatment regimen beyond 2 years in breast cancer. - Zecca E; Zambelli L; Tinè G; Bracchi P; Miceli R; Pigni A; Lo Dico S; Ricchini F; Mariani G; Massa G; Caraceni A (Breast (Edinburgh, Scotland), 2025)